Radiopharm Theranostics: Radiotherapeutic Biotech With PD-L1 And HER2 Targeting
Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
CURE5d
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced ...
EurekAlert!5d
Inhibition of PCSK9: a promising enhancer for anti-PD-1/PD-L1 immunotherapy
Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for ImmutepGlobal Phase III with ...
Pharmabiz2d
Immutep doses first patient in its TACTI-004 phase III clinical trial in first line non-small cell lung cancer
Sydney, Australia Friday, March 28, 2025, 18:00 Hrs [IST] ...
BioSpace2d
BioNTech’s Bispecific Elicits Treatment Response in Majority of SCLC Patients
BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.
Pharmabiz5d
CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer
CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer: Suzhou, China Tuesday, March 25, 2025, 17:00 Hrs [IST] C ...
Le Lézard5h
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization. In 2024, Akeso ...
Yahoo Finance5d
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
anti-PD-1 therapy KEYTRUDA® (pembrolizumab) and chemotherapy as first line treatment for patients with advanced or metastatic non-small cell lung cancer (1L NSCLC). Dr. Ina Nordman, who treated ...